Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation

References

• Ozaki K, Sato K, Oh I, Meguro A, Tatara R, Muroi K . Mechanisms of immunomodulation by mesenchymal stem cells. Int J Hematol. 2007;86:5–7.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD . Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–506.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007; 262:509–25.
   PubMed Web of Science ®Google Scholar
• Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006;312:2169–79.
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, . Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722–9.
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, . Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228–34.
   PubMed Web of Science ®Google Scholar
• Nicola MD, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.
   PubMed Web of Science ®Google Scholar
• Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D, . Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619–21.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815–22.
   PubMed Web of Science ®Google Scholar
• Oh I, Ozaki K, Sato K, Meguro A, Tatara R, Hatanaka K, . Interferon-γ and NF-κB mediate nitric oxide production by mesenchymal stromal cells. Biochem Biophys Res Commun. 2007;355:956–62.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, . A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821–8.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A, . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27:1954–62.
   PubMed Web of Science ®Google Scholar
• Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, . Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483–6.
   PubMed Web of Science ®Google Scholar
• Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 2000;165:6107–15.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–8.
   PubMed Web of Science ®Google Scholar
• Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, . Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17:375–87.
   PubMed Web of Science ®Google Scholar
• Wynn TA. TH-17: a giant step from TH1 and TH2. Nature Immunol. 2005;6:1069–70.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24: 179–89.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, . Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231–4.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, . Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371–81.
   PubMed Web of Science ®Google Scholar
• Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6:1219–27.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, . Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86.
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Med. 2003;9:1144–50.
   PubMed Web of Science ®Google Scholar
• English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156:149–60.
   PubMed Web of Science ®Google Scholar
• Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933–46.
   PubMed Web of Science ®Google Scholar
• Ianni MD, Papa BD, Ioanni MD, Moretti L, Bonifacio E, Cecchini D, . Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36: 309–18.
   PubMed Web of Science ®Google Scholar
• Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, . Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008;112:2101–10.
   PubMed Web of Science ®Google Scholar
• Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, . IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009;113: 945–52.
   PubMed Web of Science ®Google Scholar
• Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009; 113:1365–74.
   PubMed Web of Science ®Google Scholar
• Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, . Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182: 5994–6002.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, . IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature. 2007;448:483–7.
   Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, . Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448: 480–3.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, . IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunol. 2007;8:967–74.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie M, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910–14.
   PubMed Web of Science ®Google Scholar
• Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, . Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nature Med. 2009;15: 633–41.
   PubMed Web of Science ®Google Scholar
• Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, . Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206: 535–48.
   PubMed Web of Science ®Google Scholar